Skip to Content

Cabozantinib significantly prolongs PFS compared to sunitinib in papillary RCC

The results from SWOG 1500 were presented at ASCO GU 2021 and show that cabozantinib provides a statistically significant and clinically meaningful prolongation of progression-free survival compared to sunitinib in patients with metastatic papillary renal cell carcinoma.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top